DOI QR코드

DOI QR Code

The Economic Burden of Cancer in Korea in 2009

  • Kim, So Young (Office for Public Healthcare, Chungbuk National University Hospital, Chungbuk National University) ;
  • Park, Jong-Hyock (National Cancer Control Institute, National Cancer Center) ;
  • Kang, Kyoung Hee (National Cancer Control Institute, National Cancer Center) ;
  • Hwang, Inuk (National Cancer Control Institute, National Cancer Center) ;
  • Yang, Hyung Kook (National Cancer Control Institute, National Cancer Center) ;
  • Won, Young-Joo (National Cancer Control Institute, National Cancer Center) ;
  • Seo, Hong-Gwan (National Cancer Control Institute, National Cancer Center) ;
  • Lee, Dukhyoung (National Cancer Control Institute, National Cancer Center) ;
  • Yoon, Seok-Jun (Department of Preventive Medicine, Korea University College of Medicine)
  • Published : 2015.03.04

Abstract

Background: Cancer imposes a significant economic burden on individuals, families and society. The purpose of this study was to estimate the economic burden of cancer using the healthcare claims and cancer registry data in Korea in 2009. Materials and Methods: The economic burden of cancer was estimated using the prevalence data where patients were identified in the Korean Central Cancer Registry. We estimated the medical, non-medical, morbidity and mortality cost due to lost productivity. Medical costs were calculated using the healthcare claims data obtained from the Korean National Health Insurance (KNHI) Corporation. Non-medical costs included the cost of transportation to visit health providers, costs associated with caregiving for cancer patients, and costs for complementary and alternative medicine (CAM). Data acquired from the Korean National Statistics Office and Ministry of Labor were used to calculate the life expectancy at the time of death, age- and gender-specific wages on average, adjusted for unemployment and labor force participation rate. Sensitivity analysis was performed to derive the current value of foregone future earnings due to premature death, discounted at 3% and 5%. Results: In 2009, estimated total economic cost of cancer amounted to $17.3 billion at a 3% discount rate. Medical care accounted for 28.3% of total costs, followed by non-medical (17.2%), morbidity (24.2%) and mortality (30.3%) costs. Conclusions: Given that the direct medical cost sharply increased over the last decade, we must strive to construct a sustainable health care system that provides better care while lowering the cost. In addition, a comprehensive cancer survivorship policy aimed at lower caregiving cost and higher rate of return to work has become more important than previously considered.

Keywords

Cost analysis;cost of illness;cancer;health care costs;Korea

Acknowledgement

Grant : 암연구소및국가암관리사업본부 운영비

References

  1. American Cancer Society (2014). Cancer facts and figures 2014.
  2. Braun M, Mikulincer M, Rydall A, et al (2007). Hidden morbidity in cancer: spouse caregivers. J Clin Oncol, 25, 4829-34. https://doi.org/10.1200/JCO.2006.10.0909
  3. Byun JY, Yoon SJ, Oh IH, et al (2014). Economic burden of colorectal cancer in Korea. J Prev Med Public Health, 47, 84-93. https://doi.org/10.3961/jpmph.2014.47.2.84
  4. Choi JW, Cho KH, Choi Y, et al (2014). Changes in economic status of households associated with catastrophic health expenditures for cancer in South Korea. Asian Pac J Cancer Prev, 15, 2713-7. https://doi.org/10.7314/APJCP.2014.15.6.2713
  5. Drummond MF, Sculpher MJ, Torrance GW, et al (2005). Methods for the Economic Evaluation of Health Care Programmes. OUP Catalogue.
  6. Furlow B (2012). Expensive US cancer care: value for money? The Lancet Oncology, 13, 193.
  7. Grunfeld E, Coyle D, Whelan T, et al (2004). Family caregiver burden: results of a longitudinal study of breast cancer patients and their principal caregivers. Canadian Med Assoc J, 170, 1795-801. https://doi.org/10.1503/cmaj.1031205
  8. Guy GP Jr, Ekwueme DU, Yabroff KR, et al (2013). Economic burden of cancer survivorship among adults in the United States. J Clin Oncol, 31, 3749-57. https://doi.org/10.1200/JCO.2013.49.1241
  9. Hanly PA, Sharp L (2014). The cost of lost productivity due to premature cancer-related mortality: an economic measure of the cancer burden. BMC Cancer, 14, 224. https://doi.org/10.1186/1471-2407-14-224
  10. IOM (Institute of Medicine) (2013). Delivering high quality cancer care: Charting a new course for a system in crisis. Washington, DC: The National Academies Press.
  11. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA: A Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  12. Jung KW, Park S, Kong HJ, et al (2012). Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2009. Cancer Res Treat, 44, 11-24. https://doi.org/10.4143/crt.2012.44.1.11
  13. KCDC (Korea Centers for Disease Control & Prevention) (2009). national health and nutrition examination survey in 2009.
  14. Kim J, Hahm MI, Park EC, et al (2009). Economic burden of cancer in South Korea for the year 2005. J Prev Med Public Health, 42, 190-8. https://doi.org/10.3961/jpmph.2009.42.3.190
  15. Kim SG, Hahm MI, Choi KS, et al (2008). The economic burden of cancer in Korea in 2002. Eur J Cancer Care, 17, 136-44. https://doi.org/10.1111/j.1365-2354.2007.00818.x
  16. Kim SY, Chang YJ, Do YR, et al (2013). Employment status and work-related difficulties among family members of terminally Ill patients compared with the general population. Asian Pac J Cancer Prev , 14, 373-9. https://doi.org/10.7314/APJCP.2013.14.1.373
  17. KNHIC (Korea Natioanal Health Insurance Corporation) (2009). National Health Insurance Statistical Yearbook.
  18. KNIHC (Korea Natioanal Health Insurance Corporation) (2010). Health Insurance Patients Payments Survey 2009.
  19. KPHS (Korea Patient Helper Society). Available from: http://www.help114.or.kr/.
  20. Ministry of Labor (2009). Survey Report on Wage Structure in 2009.
  21. Luengo-Fernandez R, Leal J, Gray A, et al (2013). Economic burden of cancer across the European Union: a populationbased cost analysis. The Lancet Oncology, 14, 1165-74. https://doi.org/10.1016/S1470-2045(13)70442-X
  22. Mariotto AB, Yabroff KR, Shao Y, et al (2011). Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst, 103, 117-28. https://doi.org/10.1093/jnci/djq495
  23. Morden NE, Colla CH, Sequist TD, et al (2014). Choosing wisely-the politics and economics of labeling low-value services. New Engl J Med, 370, 589-92. https://doi.org/10.1056/NEJMp1314965
  24. Park JH, Park EC, Park JH, et al (2008). Job loss and reemployment of cancer patients in Korean employees: a nationwide retrospective cohort study. J Clin Oncol, 26, 1302-9. https://doi.org/10.1200/JCO.2007.14.2984
  25. Peixoto V, Faria AL, Goncalves M, et al (2014). Evolution of costs of cancer drugs in a Portuguese hospital. World J Clin Oncol, 5, 164-9. https://doi.org/10.5306/wjco.v5.i2.164
  26. Shin JY, Kim SY, Lee KS, et al (2012). Costs during the first five years following cancer diagnosis in Korea. Asian Pac J Cancer Prev, 13, 3767-72. https://doi.org/10.7314/APJCP.2012.13.8.3767
  27. Sullivan R, Peppercorn J, Sikora K, et al (2011). Delivering affordable cancer care in high-income countries. Lancet Oncol, 12, 933-80. https://doi.org/10.1016/S1470-2045(11)70141-3
  28. Tachfouti N, Belkacemi Y, Raherison C, et al (2012). First data on direct costs of lung cancer management in Morocco. Asian Pac J Cancer Prev, 13, 1547-51. https://doi.org/10.7314/APJCP.2012.13.4.1547
  29. Turkoglu N, Kilic D (2012). Effects of care burdens of caregivers of cancer patients on their quality of life. Asian Pac J Cancer Prev, 13, 4141-5. https://doi.org/10.7314/APJCP.2012.13.8.4141
  30. Ubel PA, Abernethy AP, Zafar SY (2013). Full disclosure-out-ofpocket costs as side effects. New Engl J Med, 369, 1484-6. https://doi.org/10.1056/NEJMp1306826
  31. Wani MA, Tabish SA, Jan FA, et al (2013). Cost analysis of in-patient cancer chemotherapy at a tertiary care hospital. J Cancer Res Ther, 9, 397-401. https://doi.org/10.4103/0973-1482.119314
  32. Wissinger E, Griebsch I, Lungershausen J, et al (2014). The economic burden of head and neck cancer: a systematic literature review. Pharmacoeconomics, 32, 865-82. https://doi.org/10.1007/s40273-014-0169-3
  33. Yabroff KR, Lawrence WF, Clauser S, et al (2004). Burden of illness in cancer survivors: findings from a population-based national sample. J Natl Cancer Inst, 96, 1322-30. https://doi.org/10.1093/jnci/djh255
  34. Yang SC (2013). Estimating the lifelong health impact and financial burdens of different types of lung cancer. BMC Cancer, 13, 579. https://doi.org/10.1186/1471-2407-13-579
  35. You CH, Kang S, Kwon YD, Choi JH (2013). Time trend of out-of-pocket expenditure among cancer inpatients: evidence from Korean tertiary hospitals. Asian Pac J Cancer Prev, 14, 6985-9. https://doi.org/10.7314/APJCP.2013.14.11.6985

Cited by

  1. Economic Burden for Lung Cancer Survivors in Urban China vol.14, pp.3, 2017, https://doi.org/10.3390/ijerph14030308
  2. The economic burden of advanced gastric cancer in Taiwan vol.17, pp.1, 2017, https://doi.org/10.1186/s12913-017-2609-1
  3. The Effects of a Culturally Tailored, Patient-Centered Psychosocial Intervention in South Korean Cancer Survivors pp.1552-3799, 2018, https://doi.org/10.1177/1054773818755836
  4. Cancer cost communication: experiences and preferences of patients, caregivers, and oncologists—a nationwide triad study vol.26, pp.10, 2018, https://doi.org/10.1007/s00520-018-4201-6
  5. Labour force participation and the cost of lost productivity due to cancer in Australia vol.18, pp.1, 2018, https://doi.org/10.1186/s12889-018-5297-9